Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 364

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial

Open access
Baud, Olivier, Maury, Laure, Lebail, Florence, Ramful, Duksha, El Moussawi, Fatima, Nicaise, Claire, Zupan-Simunek, Véronique, Coursol, Anne, Beuchée, Alain, Bolot, Pascal, Andrini, Pierre, Mohamed, Damir, Alberti, Corinne·2016·The Lancet

Abstract

BACKGROUND Bronchopulmonary dysplasia, a major complication of extreme prematurity, has few treatment options. Postnatal steroid use is controversial, but low-dose hydrocortisone might prevent the harmful effects of inflammation on the developing lung. In this study, we aimed to assess whether low-dose hydrocortisone improved survival without bronchopulmonary dysplasia in extremely preterm infants. METHODS In this double-blind, placebo-controlled, randomised trial done at 21 French tertiary-care neonatal intensive care units (NICUs), we randomly assigned (1:1), via a secure study website, extremely preterm infants inborn (born in a maternity ward at the same site as the NICU) at less than 28 weeks of gestation to receive either intravenous low-dose hydrocortisone or placebo during the first 10 postnatal days. Infants randomly assigned to the hydrocortisone group received 1 mg/kg of hydrocortisone hemisuccinate per day divided into two doses per day for 7 days, followed by one dose of 0·5 mg/kg per day for 3 days. Randomisation was stratified by gestational age and all infants were enrolled by 24 h after birth. Study investigators, parents, and patients were masked to treatment allocation. The primary outcome was survival without bronchopulmonary dysplasia at 36 weeks of postmenstrual age. We used a sequential analytical design, based on intention to treat, to avoid prolonging the trial after either efficacy or futility had been established. This trial is registered with ClinicalTrial.gov, number NCT00623740. FINDINGS 1072 neonates were screened between May 25, 2008, and Jan 31, 2014, of which 523 were randomly assigned (256 hydrocortisone, 267 placebo). 255 infants on hydrocortisone and 266 on placebo were included in analyses after parents withdrew consent for one child in each group. Of the 255 infants assigned to hydrocortisone, 153 (60%) survived without bronchopulmonary dysplasia, compared with 136 (51%) of 266 infants assigned to placebo (odds ratio [OR] adjusted for gestational age group and interim analyses 1·48, 95% CI 1·02-2·16, p=0·04). The number of patients needed to treat to gain one bronchopulmonary dysplasia-free survival was 12 (95% CI 6-200). Sepsis rate was not significantly different in the study population as a whole, but subgroup analyses showed a higher rate only in infants born at 24-25 weeks gestational age who were treated with hydrocortisone (30 [40%] of 83 vs 21 [23%] of 90 infants; sub-hazard ratio 1·87, 95% CI 1·09-3·21, p=0·02). Other potential adverse events, including notably gastrointestinal perforation, did not differ significantly between groups. INTERPRETATION In extremely preterm infants, the rate of survival without bronchopulmonary dysplasia at 36 weeks of postmenstrual age was significantly increased by prophylactic low-dose hydrocortisone. This strategy, based on a physiological rationale, could lead to substantial improvements in the management of the most premature neonates. FUNDING Assistance Publique-Hôpitaux de Paris.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)00202-6

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 7

  1. Walsh, 2006, Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks, Pediatrics, 118, e1328, 10.1542/peds.2006-0359 · doi:10.1542/peds.2006-0359
  2. Bonsante, 2007, Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial, Neonatology, 91, 217, 10.1159/000098168 · doi:10.1159/000098168
  3. Shah, 2012, Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants, Cochrane Database Syst Rev, 5, CD002057
  4. Autret-Leca, 2008, Postnatal glucocorticoids in preterm neonates: use in French neonatal centres in 2006, Arch Dis Child Fetal Neonatal Ed, 93, F398, 10.1136/adc.2008.141085 · doi:10.1136/adc.2008.141085
  5. Watterberg, 2005, Effect of dose on response to adrenocorticotropin in extremely low birth weight infants, J Clin Endocrinol Metab, 90, 6380, 10.1210/jc.2005-0734 · doi:10.1210/jc.2005-0734
  6. Peltoniemi, 2009, Trial of early neonatal hydrocortisone: two-year follow-up, Neonatology, 95, 240, 10.1159/000164150 · doi:10.1159/000164150
  7. Parikh, 2013, Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes, J Pediatr, 162, 685, 10.1016/j.jpeds.2012.09.054 · doi:10.1016/j.jpeds.2012.09.054

Cited by

See all 364

Metadata

Authors
Baud, O., Maury, L., Lebail, F., Ramful, D., El Moussawi, F., Nicaise, C., Zupan-Simunek, V., Coursol, A., Beuchée, A., Bolot, P., Andrini, P., Mohamed, D., & Alberti, C.
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-04
Volume
387
Issue
10030
Pages
1827-1836
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2282520777
Cited by
364
References
23
FWCI
32.04
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(16)00202-6
The paper
Baud, O., Maury, L., Lebail, F., Ramful, D., El Moussawi, F., Nicaise, C., Zupan-Simunek, V., Coursol, A., Beuchée, A., Bolot, P., Andrini, P., Mohamed, D., & Alberti, C. (2016). Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)00202-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.